Cellivery Therapeutics Valuation

Is A268600 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A268600 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A268600's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A268600's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A268600?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A268600. This is calculated by dividing A268600's market cap by their current preferred multiple.
What is A268600's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩244.94b

A268600 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.1x
Enterprise Value/EBITDA	-5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A268600's PS Ratio compare to its peers?

The above table shows the PS ratio for A268600 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.2x
A278650 HLB bioStepLtd	3.6x	n/a	₩177.2b
A038290 Macrogen	1.3x	15.6%	₩173.8b
A220100 FutureChemLtd	35.3x	n/a	₩525.9b
A039860 NanoEntek	4.6x	n/a	₩128.4b
A268600 Cellivery Therapeutics	10.9x	n/a	₩244.9b

Price-To-Sales vs Peers: A268600 is good value based on its Price-To-Sales Ratio (10.9x) compared to the peer average (16.2x).

Price to Earnings Ratio vs Industry

How does A268600's PE Ratio compare vs other companies in the KR Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.4%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: A268600 is expensive based on its Price-To-Sales Ratio (10.9x) compared to the KR Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is A268600's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A268600 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A268600's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.